Trial of the Efficacy and Safety of Short and Long Course Radiation Therapy With/Without BMX-001
Status:
Not yet recruiting
Trial end date:
2029-06-01
Target enrollment:
Participant gender:
Summary
In this Phase 2 study, we will conduct an efficacy and safety study of the combination of
investigational drug BMX-001, with short-course radiotherapy (SCRT) or long-course
chemoradiotherapy (LCCRT) as part of total neoadjuvant therapy in newly diagnosed rectal
adenocarcinoma (RAC) patients.
Phase:
Phase 2
Details
Lead Sponsor:
Chi Lin, MD, PhD
Collaborators:
BioMimetix JV, LLC National Cancer Institute (NCI)